Celularity Inc. (CELUW)

US — Healthcare Sector
Peers: CELU  EFTRW  QSIAW  HUMAW  SRZNW 

Automate Your Wheel Strategy on CELUW

With Tiblio's Option Bot, you can configure your own wheel strategy including CELUW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CELUW
  • Rev/Share 2.4769
  • Book/Share 0.4037
  • PB 4.7561
  • Debt/Equity 3.2854
  • CurrentRatio 0.383
  • ROIC -0.4707

 

  • MktCap 45982464.0
  • FreeCF/Share -0.2998
  • PFCF -7.0074
  • PE -0.5888
  • Debt/Assets 0.2188
  • DivYield 0
  • ROE -3.3523

 

  • Rating D+
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Celularity Inc. (CELUW)

  • IPO Date 2021-07-19
  • Website https://www.celularity.com
  • Industry Biotechnology
  • CEO Dr. Robert Joseph Hariri M.D., Ph.D.
  • Employees 120
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.